glp-1/gip dual agonist lilly LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor for glycemic control and weight loss: From discovery to clinical proof of concept: Cell Metabolism Move over #retatrutide the #QuintupleAgonist

doi: 10.1007/s12031-019-1257-9 170 RushA

Shotsy includes a dedicated Maintenance Mode that recalibrates your entire dashboard once you reach your target: new benchmarks, stability-focused tracking, and adjusted analytics

Holst JJ, Buse JB, Rodbard HW, Linjawi S, Woo VC, Boesgaard TW, et al

As people who are losing weight need to purchase new clothes that fit their changing bodies, this could result in a temporary surge in revenue for clothing retailers, including plus-size specialists who often cater to a broad range of sizes

While potentially being sufficient for the early rise in circulating GLP-1 upon food intake, the relative scarceness of L-cells in the proximal small intestine of both rodents and humans [208] suggests that proximal to-distal neuronal and/or humoral signals might affect the release of GLP-1 during meals [208], in particular during the early phase of GLP-1 secretion

Moreover, a decrease in atherosclerotic cardiovascular disease (ASCVD) has been found in people treated with semaglutide who were obese or overweight, but, this trend was not statistically significant [28]